Dostarlimab in dMMR Recurrent EC: Data From GARNET
Robert L. Coleman, MD, and Krishnansu S. Tewari, MD, reflect on data from the GARNET clinical trial of dostarlimab in dMMR recurrent endometrial carcinoma.
Watch
Pembrolizumab in dMMR Recurrent EC: Data From KEYNOTE-158
Shared insight on the utilization of pembrolizumab in dMMR recurrent endometrial carcinoma in the context of the KEYNOTE-158 clinical trial.
Watch
Patient Case 2: dMMR Recurrent Endometrial Carcinoma
Robert L. Coleman, MD, opens discussion on a second patient case and highlights critical aspects of mismatch repair deficient (dMMR) recurrent endometrial carcinoma.
Watch
pMMR Recurrent EC: Optimal Selection and Sequencing of Therapy
Before closing out their discussion on the first patient case, key opinion leaders on endometrial carcinoma reflect on the optimal selection and sequencing of therapy in pMMR recurrent disease.
Watch